Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

ConferencepositiveIMA401IMA402Positive

AI Analysis

Summary

Immatics presented clinical data on its IMA401 MAGEA4/8 bispecific at the 2026 ASCO Annual Meeting with concurrent publication in Nature Medicine, supporting development of the IMA401/IMA402 combination for lung cancer treatment.

Outcome Details

Data on IMA401 MAGEA4/8 bispecific presented at ASCO Annual Meeting with simultaneous publication in Nature Medicine supporting IMA401/IMA402 combination development in lung cancer

Importance:6/10

Sentiment:

0.70

bispecificMAGEA4MAGEA8lung cancercombination therapyASCONature Medicine

Related Companies

$IMTX

Read the original article

Published by yahoo_finance on May 31, 2026 1:00 PM

Read Original